INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Corporate insider
VJ

Vogelstein R Jacob

Director, 10% OwnerCIK 0002154030

EDGAR filingsOpen in network
Disclosed transactions9
Buys / sells0 / 0
Max Insider Score9
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
VJ
Vogelstein R JacobDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
742.5K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Iambic Therapeutics, Inc.Director, 10% Owner · Oct 16, 2026
9
VJ
Vogelstein R JacobDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C
—
2.00M sh
Oct 16, 2026
Oct 19, 2026
traded Oct 16, 2026
+3d
SEC FORM 4

Evidence

9
VJ
Vogelstein R JacobDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
1.46M sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
VJ
Vogelstein R JacobDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
1.14M sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
VJ
Vogelstein R JacobDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
731.2K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
VJ
Vogelstein R JacobDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
122.7K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
VJ
Vogelstein R JacobDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
1.46M sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
VJ
Vogelstein R JacobDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
742.5K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

0
VJ
Vogelstein R JacobDirector, 10% Owner
IAMIambic Therapeutics, Inc.
Grant or award · 10b5-1 plan
A—
20.3K sh
Oct 14, 2026Oct 16, 2026
traded Oct 14, 2026
+2dSEC FORM 4

Evidence